Modern approaches to the treatment of herpetic infection in children

S.O. Kramarov, V.V. Yevtushenko


It is currently known 8 pathogenic herpesviruses: two types of herpes simplex virus (HSV-1, HSV-2), varicella zoster virus, Epstein-Barr virus, cytomegalovirus, HHV-6, HHV-7, and HHV-8. Herpes simplex virus type 1 and type 2 are members of the Herpesviridae family and are characterized by their ability to establish latency after primary infection and subsequently reactivate. After lytic infection on the surface of peripheral mucosa, HSV can enter sensory neurons and establish latent infection during which viral replication ceases. Moreover, latent virus can re-enter the replication cycle by reactivation and return to peripheral tissues to start recurrent infection. Drugs used today with anti-herpesvirus activity include acyclovir, cidofovir, famciclovir, foscarnet, ganciclovir, idoxuridine, penciclovir, trifluridine, valacyclovir, valganciclovir, and vidarabine. Inosine pranobex is another antiherpetic medication with direct antiviral and immunomodulatory activity. Inosine pranobex can improve the clinical course of the recurrent herpetic infection and accelerate the normalization of immunological parameters.


herpesviruses; herpes simplex infection; treatment; inosine pranobex; children


Oliver S., James S.H. Herpes Viruses. Ref. Modul. Biomed. Sci. January 2016. doi: 10.1016/B978-0-12-801238-3.98786-5.

Cohen J.I. Human Herpesvirus Types 6 and 7 (Exanthem Subitum). Mand Douglas, Bennett’s Princ. Pract. Infect Dis. January 2015. Р. 1772-1776.e1. doi: 10.1016/B978-1-4557-4801-3.00142-9.

Parra M., Alcala A., Amoros C. et al. Encephalitis associated with human herpesvirus-7 infection in an immunocompetent adult. Virol J. 2017. 14(1). 97. doi: 10.1186/s12985-017-0764-y.

Hupp J.R., Ferneini E.M., Barakat L.A., Malinis M. Nonbacterial Microbiology of the Head, Neck, and Orofacial Region. Head, Neck, Orofac Infect. January 2016. Р. 38-59. doi: 10.1016/B978-0-323-28945-0.00003-X.

Looker K.J., Magaret A.S., May M.T. et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS One. 2015. 10(10). doi: 10.1371/JOURNAL.PONE.0140765.

Looker K.J., Magaret A.S., Turner K.M.E., Vickerman P., Gottlieb S.L., Newman L.M. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One. 2015. 10(1). Р. e114989. doi:10.1371/journal.pone.0114989.

Looker K.J., Magaret A.S., May M.T. et al. First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Heal. 2017. 5(3). Р. e300-e309. doi: 10.1016/S2214-109X(16)30362-X.

Beketova G., Savichuk N. Human viromе and its role in the formation of diseases. Herpes infection in children: current approaches to therapy. Педиатрия. Восточная Европа. 2016. № 4(1). С. 47-62.

Miller C.S., Danaher R.J. Asymptomatic shedding of herpes simplex virus (HSV) in the oral cavity. Oral Surgery, Oral Med. Oral Pathol. Oral Radiol. Endodontology. 2008. 105(1). Р. 43-50. doi: 10.1016/j.tripleo.2007.06.011.

Saleh D., Sharma S. Herpes Simplex Type 1. Stat. Pearls Publishing; 2019. 29489260. Accessed April 23, 2019.

Rechenchoski D.Z., Faccin-Galhardi L.C., Linhares R.E.C., Nozawa C. Herpesvirus: an underestimated virus. Folia Microbiol. (Praha). 2017. 62(2). 151-156. doi: 10.1007/s12223-016-0482-7.

Taketomo C.K., Hodding J.H., Kraus D.M. Pediatric and Neonatal Dosage Handbook. 21st ed. Hudson, OH: Lexi-Comp, 2014.

James S., Whitley R. Treatment of Herpes Simplex Virus Infections in Pediatric Patients: Current Status and Future Needs. Clin. Pharmacol. Ther. 2010. 88(5). Р. 720. doi: 10.1038/CLPT.2010.192.

Крамарєв С.О., Савичук Н.О., Палатна Л.О. Сучасні підходи до протирецидивної терапії герпесу шкіри та слизової оболонки порожнини рота. Педіатрія, акушерство та гінекологія. 2000. № 3. С. 23-26.

Chi C.-C., Wang S.-H., Delamere F.M., Wojnarowska F., Peters M.C., Kanjirath P.P. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane database Syst. Rev. 2015. 2015(8). CD010095. doi: 10.1002/14651858.CD010095.pub2.

FDA. Recurrent Herpes Labialis: Developing Drugs for Treatment and Prevention Guidance for Industry. 2016 (July).

Koyuncu O.O., MacGibeny M.A., Enquist L.W. Latent versus productive infection: the alpha herpesvirus switch. Future Virol. 2018. 13(6). Р. 431-443. doi: 10.2217/fvl-2018-0023.

Lasek W., Janyst M., Wolny R., Zapała Ł., Bocian K., Drela N. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm. 2015. 65(2). Р. 171-180. doi: 10.1515/acph-2015-0015.

Осипова Л.С., Сольський С.Я., Сольська Т.В. Генітальний герпес — погляд на проблему. Здоров`я киян. 2008. № 6. С. 1-3.

You Y., Wang L., Li Y. et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J. Dermatol. 2015. 42(6). Р. 596-601. doi: 10.1111/1346-8138.12845.

Copyright (c) 2019 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта